Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR9 | P51686 | 16/20 | 0.48 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL344142 | 0.89 | CCR9 (0.63) | CCR9LMNAHTT | |
| SCHEMBL13815983 | 0.83 | CCR9 (0.54) | CCR9BDKRB1LMNAHTT | |
| SCHEMBL342185 | 0.74 | CCR9 (0.79) | CCR9LMNAHTT | |
| SCHEMBL344024 | 0.72 | CCR9 (0.69) | CCR9LMNAHTT | |
| SCHEMBL342783 | 0.72 | CCR9 (0.76) | CCR9LMNAHTT | |
| SCHEMBL15761703 | 0.69 | CCR9 (0.79) | CCR9LMNAHTT | |
| SCHEMBL344936 | 0.69 | CCR9 (0.86) | CCR9LMNAHTT | |
| SCHEMBL342112 | 0.69 | CCR9 (0.63) | CCR9LMNAHTT | |
| SCHEMBL10248265 | 0.68 | BDKRB1 (0.73) | CCR9BDKRB1 | |
| SCHEMBL10284581 | 0.68 | CCR9 (0.62) | CCR9BDKRB1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163498-A1 | Aryl Sulfonamides | CHEMOCENTRYX, INC. (US) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163498-A1 | Aryl Sulfonamides | CCR9, CCR1, CCR2 | CCR9 1/4885BDKRB1 429/4885CA12 2282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.